Trial Profile

A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetrelimab (Primary) ; JNJ 86974680 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors Johnson & Johnson Innovation

Most Recent Events

30 Apr 2025 Initial results (n=41) assessing safety, pharmacokinetics, and preliminary efficacy of JNJ-86974680 as a monotherapy, and in combination with cetrelimab, in patients with NSCLC, presented at the 116th Annual Meeting of the American Association for Cancer Research.
31 Jan 2025 Planned number of patients changed from 76 to 126.
31 Jan 2025 Planned End Date changed from 3 Aug 2028 to 7 Jun 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com